
虽然NETs我们已经做了不少了,但是依然感觉体外诱导的NETs有时候不是很稳定,想得到漂亮的图还需要努力一番,同时,组织水平的NETs免疫荧光双标的结果总是差强人意,所以现在就只能多看看别人的结果是怎样的了。
先看一下关于Figure S5E和Figure 3I的原文描述:Both reagents, effectively suppressing NETs in primary neutrophil culture (Figure S5E) and in lungs of doxorubicin-treated mice (Figures 3H and 3I)。体外的NETs IF双标结果还行,我们也能做出来这样的,但有个点我比较好奇,PMA诱导后的视野中并不是整个一大片都是NETs,而是呈现出一定的聚集特征,即有些区域NETs很少,有些区域基本没有,所以如果我是审稿人,我会要求提供低倍镜下可以展示全貌的图。体外NETs IF染色结果citH3的信号可以看出来是非常弱的,同样,展示出低倍镜下的更全的视野这个结果才会更让人信服。

Figure S5E 小鼠原代中性粒细胞来源的NETs(标记物Ly6G+citH3)

Figure 3I 小鼠肺组织中NETs标记物(Ly6G+citH3)染色
原文表述:To verify the effects of these factors on NETosis, we treated murine bone marrow–derived neutrophils with murine recombinant C3a, CXCL1 and MIF proteins, and observed potent induction of NETosis (Figure 6C; Figure S7N).

Figure 6C 骨髓来源中性粒细胞用重组小鼠C3a蛋白处理后IF染色
原文表述:Doxorubicin pretreatment enhanced NET formation and metastatic growth of the syngeneic breast cancer cell line Py8119 in wild-type mice, but C3 knockout in host mice partially blocked the influence of doxorubicin (Figures 6E–6G; Figure S7W), indicating C3 as a major but not the sole factor for senescence-induced NETosis.

Figure 6E 肿瘤细胞接种7天后肺部NETosis
原文表述:Multiplex IF staining confirmed the upregulation of C3, NETs, and tumor cell proliferation in the lungs of chemotherapy- treated mice (Figures 7A and 7B).

Figure 7A 4T1原位乳腺癌小鼠肺组织多色荧光标记(包括NETs标记物)
原文描述:IF staining of lung metastases of breast cancer patients showed that the expression levels of C3, CXCL1, and MIF were all positively correlated with NET formation (Figures 7C and 7D).

Figure 7C 不同NETs水平的乳腺癌患者的肺组织多荧光染色
原文描述:In the model of adjuvant chemotherapy, DQ treatment inhibited NETosis and DTC proliferation in lung (Figures 8A and 8B).

Figure 8A 小鼠原位4T1乳腺癌组织中NETs IF双标。
总体来看,这些图片都还是挺好看的,但这些图片是否是精心挑出来的,说实话,只有做实验的人才知道。但我总体上还是相信高分论文的数据的,因为一般来说,发高分文章的课题组更有钱,期刊的要求也会更高,审稿人也更牛逼。
希望大家的NETs染色结果也能很漂亮,不用精心挑选图片!
图片来自于文献
1. He D, Wu Q, Tian P, et al. Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps[J]. Cancer Cell, 2025.